A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer.
A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer.
复制标题
DOI：
10.7150/ijbs.23182
复制
发表时间：
2018
影响因子：
9.2
通讯作者：
Hsieh JC
中科院分区：
文献类型：
--
作者：
Chou WC;Wu MH;Chang PH;Hsu HC;Chang GJ;Huang WK;Wu CE;Hsieh JC
背景：迫切需要为接受化疗的转移性结直肠癌（mCRC）患者开发可靠的预后生物标志物。目前的研究旨在检查循环肿瘤细胞（CTC）的预后意义，并开发一个预后模型，将CTC纳入化疗治疗的mCRC患者的预后预测。方法：我们的研究前瞻性纳入了55例在2011年至2014年期间接受姑息化疗的mCRC患者。使用单变量分析确定基线CTC和预测生存结局的临床病理学变量。使用基于阴性选择的方案加流式细胞术进行CTC鉴定。结果：中位总生存期（OS）和无进展生存期（PFS）分别为24.2个月和8.7个月。所有患者均检测到CTC，CTC的中位数为30.8/mL（范围：5.8-431.3/mL）。CTC数≤30/mL患者的中位OS和PFS分别为37.1个月和13.3个月，而CTC数>30/mL患者的中位OS和PFS分别为14.9个月和5.1个月（均P<0.001）。使用CTC结合其他独立临床变量的预后模型进一步将患者分为良好和不良预后组。预后良好组的中位OS和PFS分别为32.4和11.5个月，预后不良组的中位OS和PFS分别为5.4和2.7个月。结论：我们开发了一个可靠的基于CTC的预后模型，用于预测接受化疗的mCRC患者的临床结局。该模型可用于帮助临床医生在治疗前识别预后最差的患者。
Background: There is an urgency to develop robust prognostic biomarkers for metastatic colorectal cancer (mCRC) patients receiving chemotherapy. The current study aimed to examine the prognostic significance of circulating tumour cells (CTCs) and to develop a prognostic model incorporating CTCs in predicting the outcomes of mCRC patients treated with chemotherapy. Methods: Our study prospectively enrolled 55 mCRC patients who had undergone palliative chemotherapy between 2011 and 2014. Baseline CTCs and clinicopathological variables predictive of survival outcome were identified using univariate analysis. Negative selection-based protocol plus flow cytometry was used for CTC identification. Results: The median overall survival (OS) and progression-free survival (PFS) were 24.2 months and 8.7 months, respectively. CTCs were detected in all the patients, and the median number of CTCs was 30.8/mL (range: 5.8-431.3/mL). The median OS and PFS were 37.1 and 13.3 months, respectively, for patients with CTC number ≤30/mL, while the median OS and PFS were 14.9 months and 5.1 months, respectively, for patients with CTC number >30/mL (both P<0.001). A prognostic model using CTCs in conjunction with other independent clinical variables further stratified patients into good and poor prognostic groups. The median OS and PFS were 32.4 and 11.5 months, respectively, in the good prognostic group and 5.4 and 2.7 months, respectively, in the poor prognostic group. Conclusions: We developed a reliable CTC-based prognostic model for the prediction of clinical outcomes in mCRC patients treated with chemotherapy. This model may be used to assist clinicians in identifying those with the poorest prognosis before treatment.
登录
查看更多内容
影响因子：
158.5
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
通讯作者：
Hayes, DF
在微流体系统中使用光学诱导的二卫生到循环肿瘤细胞中用于基因表达分析 - 癌细胞系模型。
影响因子：
4.6
作者：
Chiu TK;Chou WP;Huang SB;Wang HM;Lin YC;Hsieh CH;Wu MH
通讯作者：
Wu MH
影响因子：
5.7
作者：
Chen D;Wen X;Song YS;Rhee YY;Lee TH;Cho NY;Han SW;Kim TY;Kang GH
通讯作者：
Kang GH
影响因子：
3.7
作者：
Knox, Robert D.;Luey, Nathan;Gill, Anthony J.
通讯作者：
Gill, Anthony J.
影响因子：
11.5
作者：
Riethdorf, Sabine;Fritsche, Herbert;Pantel, Klaus
通讯作者：
Pantel, Klaus